Menu
  • Join
  • Login
  • Contact
 

Search abstracts


AMANTADINE DEVELOPS DRUG TOXIC SYMPTOM IN A PATIENT WITH LATE EFFECTS OF CEREBRAL INFARCTION

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: WATANABE, Yoshiteru (Tohoku Medical and Pharmaceutical University Hospital, Pharmacy, Japan)
  • Co-author(s): Yoshiteru Watanabe: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
    Takashi Uno: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
    Miho Utsumi: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
    Masashi Nakamura: Neurology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
    Kensuke Usui: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
    Kouji Okada: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
    Eiji Suzuki: Psychiatry, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
    Ichiro Nakashima: Neurology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
  • Abstract:

    Background

    Amantadine acts on dopamine neurons and is used to treat the symptoms of Parkinson's disease. This drug improves the spontaneity decrease with late effects of cerebral infarction.

    Methods

    A 70s-year-old female patient with cerebral infraction was hospitalized in our hospital and she was treated for the acute phase.

     

    Results

    On the

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses